<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927131</url>
  </required_header>
  <id_info>
    <org_study_id>FLQ-01-IB</org_study_id>
    <nct_id>NCT03927131</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine</brief_title>
  <official_title>Double-blind, Randomized Clinical Trial With Active Controls to Assess Safety, Immunogenicity and Lot-to-lot Consistency of Inactivated Split-virion Quadrivalent Influenza Vaccine of Butantan Institute</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação Butantan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have showed that a broader spectrum influenza vaccine may help in reducing the&#xD;
      influenza burden of disease. Butantan Institute is currently developing a quadrivalent&#xD;
      influenza vaccine candidate. This study is will provide safety and immunogenicity data on&#xD;
      this quadrivalent influenza vaccine candidate.&#xD;
&#xD;
      The study will be conducted in an open population of healthy participants (3 years old and&#xD;
      above) recruited in different clinical sites in Brazil and will be adequately powered to&#xD;
      assess safety, immune response (measured by GMT HI antibodies) to each viral strain in the&#xD;
      vaccines and lot-to-lot consistency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded, randomized active-control comparator study to assess the safety and&#xD;
      immunogenicity of QIV-IB, the Butantan Institute quadrivalent influenza vaccine candidate. As&#xD;
      active controls, two trivalent influenza vaccines with different Influenza B strains, one&#xD;
      with influenza B/Victoria strain (TIVV-IB) and other with influenza B/Yamagata strain&#xD;
      (TIVY-IB) The study is designed to build a safety database of the quadrivalent influenza&#xD;
      vaccine in adults to detect adverse events with a frequency of 1:1000 or higher and safety&#xD;
      databases for elderly and pediatric age groups to detect adverse events with frequency of&#xD;
      1:100 or higher.&#xD;
&#xD;
      In terms of immune response, the study aims to demonstrate superiority of HI (Hemagglutinin&#xD;
      inhibition) GMT (Geometric Mean Titer) of the QIV-IB for the Influenza B strain that is not&#xD;
      present in each trivalent vaccine control. Regarding the Influenza A and B strains common to&#xD;
      QIV-IB and both trivalent vaccine controls, the study aims to demonstrate non-inferiority on&#xD;
      those strains.&#xD;
&#xD;
      Finally, a lot-to-lot consistency test will be performed in a sub-group of adult&#xD;
      participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of QIV-IB per age group</measure>
    <time_frame>42 days post-vaccination</time_frame>
    <description>Frequency and intensity of adverse events reactions and events of special interest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority for influenza B/Victoria strain</measure>
    <time_frame>21 days post-vaccination</time_frame>
    <description>HI GMT ratio for Influenza B/Victoria strains between QIV-IB and TIVY-IB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority for influenza B/Yamagata strain</measure>
    <time_frame>21 days post-vaccination</time_frame>
    <description>HI GMT ratio for Influenza B/Yamagata strains between QIV-IB and TIVY-IB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inferiority for common influenza strains between QIV-IB, TIVV-IB and TIVV-IB</measure>
    <time_frame>21 days post-vaccination</time_frame>
    <description>HI GMT ratios for Influenza strains between QIV-IB, TIVV-IB and TIVV-IB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lot-to-lot consistency for immune response to different lots of QIV-IB</measure>
    <time_frame>21 days post-vaccination</time_frame>
    <description>HI GMT ratios for Influenza strains between QIV-IB, TIVV-IB and TIVV-IB</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">6528</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>QIV-IB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated split-virion quadrivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVV-IB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVY-IB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV-IB Lot A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated split-virion quadrivalent influenza vaccine - Lot A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV-IB Lot B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated split-virion quadrivalent influenza vaccine - Lot B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV-IB Lot C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactivated split-virion quadrivalent influenza vaccine - Lot C</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV-IB</intervention_name>
    <description>Inactivated split-virion quadrivalent influenza vaccine</description>
    <arm_group_label>QIV-IB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIVV-IB</intervention_name>
    <description>Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage</description>
    <arm_group_label>TIVV-IB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIVY-IB</intervention_name>
    <description>Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage</description>
    <arm_group_label>TIVY-IB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV-IB Lot A</intervention_name>
    <description>Inactivated split-virion quadrivalent influenza vaccine - Lot A</description>
    <arm_group_label>QIV-IB Lot A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV-IB Lot B</intervention_name>
    <description>Inactivated split-virion quadrivalent influenza vaccine - Lot B</description>
    <arm_group_label>QIV-IB Lot B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV-IB Lot C</intervention_name>
    <description>Inactivated split-virion quadrivalent influenza vaccine - Lot C</description>
    <arm_group_label>QIV-IB Lot C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 3 years or older at the time of enrollment.&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Agrees to complete all study visits, procedures and contacts&#xD;
&#xD;
          -  Women and adolescents of childbearing age: Negative pregnancy test with understanding&#xD;
             (through informed consent process).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic medical conditions such as psychiatric conditions, diabetes, hypertension or&#xD;
             any other conditions that might place the subjects at high risk of adverse events.&#xD;
             Study clinicians will use clinical judgment on a case-by-case basis to assess safety&#xD;
             risks under this criterion.&#xD;
&#xD;
          -  Clinically significant abnormalities on physical examination.&#xD;
&#xD;
          -  Use of immunosuppressive medications such as systemic corticosteroids or&#xD;
             chemotherapeutics, or immunosuppressive illness.&#xD;
&#xD;
          -  Women who are pregnant or planning to become pregnant during the study period plus 3&#xD;
             months beyond the last vaccine dose and currently nursing women.&#xD;
&#xD;
          -  Participation in research involving another investigational product within 30 days&#xD;
             before planned date of first vaccination or anytime through the last study safety&#xD;
             visit.&#xD;
&#xD;
          -  Clinically significant abnormalities on basic laboratory screening tests.&#xD;
&#xD;
          -  Acute febrile illness (axillar temperature ≥ 37.8°C)&#xD;
&#xD;
          -  Hypersensitivity to egg or chicken proteins or any of the vaccine constituents&#xD;
&#xD;
          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination&#xD;
&#xD;
          -  Unstable chronic illness (defined as illness requiring hospitalization or a clinically&#xD;
             significant change in medication in the previous 12 weeks).&#xD;
&#xD;
          -  Alcohol abuse of alcohol or drug addiction&#xD;
&#xD;
          -  Any vaccination within the previous 4 weeks For immune response groups&#xD;
&#xD;
          -  Seasonal influenza vaccination in the previous or current years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Butantan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <phone>+55 11 3723-2121</phone>
    <email>ricardo.palacios@butantan.gov.br</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

